Table 1.
Demographic and basic characteristics of the study population.
| 1st vaccine | NVX-CoV2373 | BNT162b2 | mRNA-1273 | |
|---|---|---|---|---|
| 2nd vaccine | NVX-CoV2373 | BNT162b2 | mRNA-1273 | |
| n = 22 | n = 22 | n = 22 | p-value | |
| Years of age (mean±SD) | 47.3 ± 14.1 | 47.0 ± 14.6 | 47.8 ± 14.7 | 0.988 |
| Female sex, n (%) | 13 (59.1) | 14 (63.6) | 14 (63.6) | 0.938 |
| Weeks between 1st and 2nd vaccination, (mean±SD) | 21.5 ± 1.5 | 31.2 ± 9.5 | 40.2 ± 4.0 | n.a. |
| Analysis time [days after 2nd vaccination], median (IQR) | 15 (2) | 14 (1) | 15 (2) | p = 0.712 |
| Differential blood cell counts | n = 22 | n = 21 | n = 22 | |
| Leukocytes (cells/µl), median (IQR) | 7100 (1625) | 6400 (2350) | 7900 (2150) | p = 0.057 |
| Granulocytes (cells/µl), median (IQR) | 4459 (1777) | 3549 (2108) | 5033 (1830) | p = 0.023 |
| Monocytes (cells/µl), median (IQR) | 559 (289) | 529 (230) | 632 (176) | p = 0.109 |
| Lymphocytes (cells/µl), median (IQR) | 2087 (455) | 2215 (792) | 2124 (1128) | p = 0.916 |
| Lymphocyte subpopulations | n = 21 | n = 16 | n = 21 | |
| CD3 T-cells (cells/µl), median (IQR) | 1556 (567) | 1572 (884) | 1636 (1068) | p = 0.846 |
| CD4 T-cells (cells/µl), median (IQR)# | 971 (378) | 933 (518)1 | 1073 (595) | p = 0.970 |
| CD8 T-cells (cells/µl), median (IQR)# | 327 (193) | 348 (365) | 402 (177) | p = 0.653 |
| CD19 B-cells (cells/µl), median (IQR)# | 152 (125) | 199 (176) | 169 (160) | p = 0.291 |
| Plasmablasts (cells/µl), median (IQR)# | 0.49 (0.455) | 0.369 (0.544) | 0.678 (0.655) | p = 0.128 |
#
Counts of CD4 and CD8 T-cells were calculated on 10 BNT162b2-vaccinated and on 19 mRNA-1273-vaccinated individuals, respectively.